Navigating the Future of Preclinical Research: Aligning with the FDA’s Roadmap on Animal Testing

The Food and Drug Administration’s (FDA) recent Roadmap to Reducing Animal Testing in Preclinical Safety Studies  marks a pivotal shift toward the adoption of innovative, human-relevant methodologies commonly known as New Approach Methodologies (NAMs).

As leaders in preclinical research tools, we welcome this movement towards advanced and validated NAMs solutions already in place.  emka TECHNOLOGIES & SCIREQ’s diverse   have helped researchers generate high-quality, reproducible data without the need to rely solely on traditional animal models. These alternatives play an increasingly vital role in early-stage drug safety and efficacy assessments.